Boston Scientific Co. (NYSE:BSX) Shares Purchased by Marks Group Wealth Management Inc

Marks Group Wealth Management Inc lifted its holdings in Boston Scientific Co. (NYSE:BSX) by 0.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 113,917 shares of the medical equipment provider’s stock after acquiring an additional 615 shares during the period. Boston Scientific makes up 0.9% of Marks Group Wealth Management Inc’s portfolio, making the stock its 28th biggest position. Marks Group Wealth Management Inc’s holdings in Boston Scientific were worth $9,546,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the business. Crestwood Advisors Group LLC increased its holdings in Boston Scientific by 1.2% in the 3rd quarter. Crestwood Advisors Group LLC now owns 66,531 shares of the medical equipment provider’s stock valued at $5,575,000 after purchasing an additional 810 shares in the last quarter. Pittenger & Anderson Inc. acquired a new stake in shares of Boston Scientific in the third quarter valued at about $419,000. FSM Wealth Advisors LLC raised its holdings in shares of Boston Scientific by 5.3% during the 3rd quarter. FSM Wealth Advisors LLC now owns 6,477 shares of the medical equipment provider’s stock valued at $543,000 after buying an additional 327 shares during the period. Impax Asset Management Group plc lifted its position in Boston Scientific by 17.5% during the 3rd quarter. Impax Asset Management Group plc now owns 5,470,174 shares of the medical equipment provider’s stock worth $457,138,000 after acquiring an additional 815,403 shares in the last quarter. Finally, Quintet Private Bank Europe S.A. grew its position in Boston Scientific by 26.3% in the third quarter. Quintet Private Bank Europe S.A. now owns 23,581 shares of the medical equipment provider’s stock valued at $1,976,000 after acquiring an additional 4,914 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on BSX shares. TD Cowen upped their target price on shares of Boston Scientific from $86.00 to $100.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Needham & Company LLC reiterated a “hold” rating on shares of Boston Scientific in a research note on Thursday, October 31st. Morgan Stanley raised their price objective on Boston Scientific from $92.00 to $100.00 and gave the company an “overweight” rating in a research note on Thursday, October 24th. Raymond James upped their target price on Boston Scientific from $91.00 to $94.00 and gave the company a “strong-buy” rating in a research report on Wednesday, September 4th. Finally, Deutsche Bank Aktiengesellschaft raised their price target on shares of Boston Scientific from $73.00 to $78.00 and gave the stock a “hold” rating in a research report on Thursday, July 25th. Four investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Boston Scientific currently has a consensus rating of “Moderate Buy” and an average price target of $93.39.

Insider Buying and Selling at Boston Scientific

In other news, EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $81.70, for a total transaction of $570,511.10. Following the transaction, the executive vice president now directly owns 37,468 shares of the company’s stock, valued at approximately $3,061,135.60. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $81.70, for a total value of $570,511.10. Following the completion of the transaction, the executive vice president now directly owns 37,468 shares in the company, valued at $3,061,135.60. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Michael F. Mahoney sold 162,777 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $84.63, for a total value of $13,775,817.51. Following the sale, the chief executive officer now directly owns 1,572,096 shares in the company, valued at approximately $133,046,484.48. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 309,270 shares of company stock valued at $26,196,718 in the last quarter. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Stock Up 1.0 %

Boston Scientific stock opened at $85.54 on Wednesday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.14 and a current ratio of 1.61. Boston Scientific Co. has a one year low of $50.84 and a one year high of $88.79. The company has a 50-day simple moving average of $84.21 and a 200-day simple moving average of $78.68. The firm has a market capitalization of $125.97 billion, a P/E ratio of 70.69, a P/E/G ratio of 2.46 and a beta of 0.79.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 EPS for the quarter, beating the consensus estimate of $0.59 by $0.04. The company had revenue of $4.21 billion for the quarter, compared to analyst estimates of $4.04 billion. Boston Scientific had a net margin of 11.26% and a return on equity of 17.41%. Boston Scientific’s revenue was up 19.3% compared to the same quarter last year. During the same quarter last year, the business earned $0.50 earnings per share. As a group, equities analysts expect that Boston Scientific Co. will post 2.46 earnings per share for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.